Overview

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

Phase:

Phase 3

Details

Lead Sponsor:

Allergan
Durata Therapeutics Inc., an affiliate of Allergan plc

Treatments:

Dalbavancin
Teicoplanin